JP Morgan Maintains Overweight on IQVIA Holdings, Raises Price Target to $285

VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast

Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.

Medera Presents Late-Breaking Clinical Trial Data at ESC Congress 2026 Demonstrating Durable Improvement in HFpEF Cardiac Filling Pressures Following SRD-002 Gene Therapy

Medera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial showing that 80% of patients met the prespecified threshold for normalization of cardiac filling pressures, with approximately 30% reduction in peak exercise pulmonary capillary wedge pressure. The trial demonstrated a favorable safety profile with no treatment-related serious adverse events across all 10 treated patients. Results support advancement to a randomized Phase 2b trial for SRD-002, a single-dose intracoronary AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction.

[Latest] Global eClinical Solutions Market Size/Share Worth USD 42.55 Billion by 2035 at a 13.98% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.

IQVIA And Medera Announce Strategic Collaboration To Accelerate Cardiac Gene Therapy Development And Human-Based Drug Discovery Platforms